Core Insights - The Dow Jones Industrial Average closed down 557.24 points (-1.18%) on November 17, 2025, influenced by upcoming earnings reports and a backlog of economic data [1] - Anticipation surrounds key corporate earnings from Nvidia, Walmart, and Home Depot, which are expected to provide insights into the AI, technology, and consumer sectors [1] - Delayed economic data, including the September jobs report, is expected to impact perceptions of the U.S. economy and Federal Reserve interest rate decisions [1] Company Performance - Johnson & Johnson, Amgen, and Merck & Co. were among the biggest gainers, reflecting a shift towards defensive or healthcare-related stocks amid market uncertainty, with gains of 2.08%, 1.82%, and 1.11% respectively [2] - American Express led the declines with a drop of 2.37%, attributed to increased net write-off rates in U.S. Consumer Card Member loans, followed by IBM (-2.13%), Salesforce (-1.94%), and Apple (-1.73%) [3]

Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer mentioned in his latest comments. Cramer highlighted the company’s breakthrough medicine, as he remarked: “We had Amgen on the show the other day, announcing a breakthrough in Repatha, its every other week injection squelches cholesterol to a level where it helps prevent heart attacks. Why not go buy that?” Photo by Yiorgos Ntrahas on Unsplash Amgen Inc. (NASDAQ:AMGN) delivers human therapeutics for conditions such as cancer, cardiovascular dise ...

Key Points It appears that some investors took a pair of new and bullish pundit takes to heart. One of the pair was a famous stock picker who appears regularly on TV. 10 stocks we like better than Amgen › The stock of pharmaceutical company Amgen (NASDAQ: AMGN) didn't exactly have a banner trading session on Thursday. In closing the day nearly flat, however, to notch a slight beat on the S&P 500 (SNPINDEX: ^GSPC). The benchmark indicator slumped by almost 1.7% on Thursday. Amgen was mentioned posit ...

So, let's go a little deeper here on on what's been winning and you you know because we've been talking about it a lot lately of this healthc care trade. Biotech has been rallying after a couple years of underperformance. It has come to life and in a big way as I said monthto date 6.5% for that space.New 52- week high for healthcare. The XBI is coming off a fresh high for this year. Bill, you bought more Amgen which hit a 52- week high today.Carrie owns it in her charitable trust. Tell us more. I I think we ...

Core Insights - The healthcare sector, particularly biotech, is experiencing a significant rally, with a month-to-date increase of 6.5% and new 52-week highs being reached [1][2] - Amgen has reported strong earnings, with earnings per share of 564 compared to 497, driven by positive performance from its cardiovascular drug Repatha [3] - The current market narrative suggests a secular bull market, with healthcare and financials leading the way [2] Biotech Sector Performance - Biotech stocks have been oversold for years, but recent attention is shifting as the market recognizes potential overvaluation in other sectors [5] - UNH has been a catalyst for the healthcare sector, showing a 45% increase since its bottom, which has raised awareness among investors [5] - The sector is benefiting from strategic deals, such as those made by Lilly and Novo, which can improve profitability despite price pressures [6] Company-Specific Insights - Bristol-Myers Squibb is trading at seven times earnings with a 5% dividend yield, while Regeneron is at 14 times earnings with a 6% free cash flow yield, both showing significant price increases in recent months [8][9] - Regeneron has one of the largest drug pipelines in the pharma and biotech industry, contributing to its strong performance [9] - Companies in the sector are expected to leverage AI for better research and efficiency, potentially revolutionizing their operations [10][11] Market Trends - The biotech sector is seeing a resurgence after a prolonged period of underperformance, with several stocks showing upward momentum [12][13] - There is potential for growth in the number of biotech companies gaining investor attention, as more names are expected to emerge as viable investment opportunities [14]

Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently put under a microscope. Cramer showed quite a bullish sentiment toward the company’s stock, as he remarked: “If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… Amgen’s working on cholesterol with its Repatha injection, and it’s doing something very different with weight loss that could lead to terrific outcomes. They both have yields, more than 2.7%. How s ...

Core Insights - High-rolling investors are bullish on Amgen (NASDAQ:AMGN), indicating potential privileged information influencing their trading decisions [1] - The sentiment among major traders is predominantly bullish, with 75% of options trades being calls and only 0% bearish [2] - Significant price targets for Amgen have been identified, ranging from $290.0 to $400.0 over the last three months [3] Options Trading Activity - A total of 8 options trades were detected for Amgen, with a notable imbalance favoring calls over puts [1][2] - The total trade price for the identified options includes $422,130 for calls and $30,600 for a put [2] - Recent options trades include various strike prices, with significant trades such as a bullish call for $400.00 expiring on January 16, 2026, totaling $180.6K [8] Company Overview - Amgen is a leader in biotechnology, known for its therapeutics including Epogen, Neupogen, and Enbrel, among others [9] - The company has expanded its portfolio through acquisitions and recent drug launches, including treatments for cancer and rare diseases [9] - Amgen's current market position is supported by expert ratings, with an average target price of $314.67 from three analysts [11][12] Current Market Status - Amgen's stock is currently trading at $337.81, reflecting a 0.45% increase [14] - The stock's trading volume is reported at 163,220, with RSI readings suggesting it may be overbought [14] - Anticipated earnings release is scheduled in 82 days, which may impact future trading activity [14]

Futures tied to the Dow Jones Industrial Average (YM=F) rose 0.2%. S&P 500 (ES=F) futures added 0.2%. Nasdaq 100 (NQ=F) futures gained 0.3%. The Mini Dow Jones Industrial Average December 2025 contract traded at 48,391, up 23 points (+0.05%) at 4:20 AM EST. The moves signaled a more stable start after days of political tension. Still, futures only hint at the trading mood and do not guarantee direction once markets open. The House passed the shutdown-ending bill in a 222–209 vote. The Congressional Budget ...

Group 1: Pharmaceutical and Biotechnology Sector - Scotiabank initiated coverage on major pharmaceutical and biotech firms with "sector outperform" ratings, setting price targets of $140 for Gilead Sciences (GILD), $1165 for Eli Lilly (LLY), $105 for Merck & Co Inc (MRK), $385 for Amgen Inc (AMGN), and $230 for Johnson & Johnson (JNJ) [2][8] Group 2: Global Market Performance - The ASX 200 Index in Australia declined by 0.52%, closing at 8753.40 points, indicating mixed sentiment in the Asia-Pacific region [3][8] - The Japanese bond market showed stability as super long bond yields eased, suggesting continued demand for longer-dated Japanese government bonds following a firm auction outcome [3][8] Group 3: Energy Sector - Gerdes Energy Research raised its price target for Chevron Corp (CVX) by $1 to a new target of $171, reflecting a positive outlook for the oil major amidst ongoing market dynamics [4][8] Group 4: Currency Markets - The Euro remained stable, trading near 1.1600 against the US Dollar after the US government ended its shutdown, providing clarity for currency traders [5][8] - The Pound Yen held steady above 203.00, near a two-week high, as traders awaited further economic indicators from the UK [5][8]

Group 1 - Recent underperformance in the packaged consumer goods sector presents investment opportunities, with Procter & Gamble (PG.US) and Kimberly-Clark (KMB.US) identified as undervalued quality companies [1] - Wall Street's pessimism towards the packaged consumer goods industry is attributed to high inflation and insufficient growth, but inflation may be nearing its peak, potentially lowering costs for consumer giants [1] - The Trump administration's lenient antitrust enforcement may facilitate mergers, allowing companies to gain market dominance [1] Group 2 - Clorox (CLX.US) is highlighted as one of the worst performers in the S&P 500, with its cleaning products and brands like Burt's Bees, Hidden Valley, and Brita being favored [2] - General Mills (GIS.US) is suggested for risk-tolerant investors, contingent on a potential acquisition, as weight-loss drugs are impacting food stocks [2] - A shift in focus from traditional consumer goods to the pharmaceutical sector is recommended, with Johnson & Johnson (JNJ.US) and Amgen (AMGN.US) seen as promising due to anticipated large-scale mergers [2]